Dividendos de Nanologica

Dividendo controles de criterios 0/6

Nanologica no tiene historial de pago de dividendo.

Información clave

n/a

Rentabilidad por dividendo

n/a

Ratio de pago

Rentabilidad media de la industria	1.8%
Próxima fecha de pago de dividendos	n/a
Fecha ex dividendo	n/a
Dividendo por acción	n/a
Beneficios por acción	-kr1.81
Rentabilidad por dividendo prevista a 3 años	n/a

Últimas actualizaciones de dividendos

No hay actualizaciones

Recent updates

Shareholders Are Thrilled That The Nanologica (NGM:NICA) Share Price Increased 115%

Feb 23

Estabilidad y crecimiento de los pagos

Obteniendo datos sobre dividendos

Dividendo estable: No hay datos suficientes para determinar si los dividendos por acción de NICA han sido estables en el pasado.

Dividendo creciente: Datos insuficientes para determinar si los pagos de dividendos de NICA han aumentado.

Rentabilidad por dividendo vs. Mercado

Rentabilidad por dividendo de Nanologica vs. Mercado

¿Cómo se compara la rentabilidad por dividendo de NICA con la del mercado?
Segmento	Rentabilidad por dividendo
Empresa (NICA)	n/a
Suelo de mercado 25% (SE)	1.6%
Techo de mercado 25% (SE)	4.4%
Media de la industria (Biotechs)	1.8%
Previsión de analistas en 3 años (NICA)	n/a

Dividendo destacado: No es posible evaluar la rentabilidad por dividendo de NICA en comparación con el 25% inferior de los pagadores de dividendos, ya que la empresa no ha comunicado ningún pago reciente.

Alto dividendo: No es posible evaluar la rentabilidad por dividendo de NICA en comparación con el 25% de los principales pagadores de dividendos, ya que la empresa no ha comunicado ningún pago reciente.

Pago de beneficios a los accionistas

Cobertura de los beneficios: No hay datos suficientes para calcular el ratio de pago de NICA para determinar si sus pagos de dividendos están cubiertos por los beneficios.

Pago en efectivo a los accionistas

Cobertura de flujo de caja: No es posible calcular la sostenibilidad de los dividendos, ya que NICA no ha comunicado ningún pago.

Dividendos de Nanologica

Dividendo controles de criterios 0/6

Información clave

Últimas actualizaciones de dividendos

Recent updates

New major risk - Financial position

First quarter 2024 earnings released: kr0.46 loss per share (vs kr0.34 loss in 1Q 2023)

Nanologica AB (publ) Announces Chief Operating Officer Changes

New minor risk - Shareholder dilution

Full year 2023 earnings released: kr2.08 loss per share (vs kr1.84 loss in FY 2022)

Price target decreased by 25% to kr12.00

Full year 2023 earnings released: kr2.08 loss per share (vs kr1.84 loss in FY 2022)

Nanologica AB (publ) to Report Q2, 2024 Results on Jul 05, 2024

Insufficient new directors

New minor risk - Share price stability

Nanologica AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 54.2 million.

New major risk - Financial position

Third quarter 2023 earnings released: kr0.32 loss per share (vs kr0.39 loss in 3Q 2022)

Nanologica AB (publ), Annual General Meeting, May 16, 2024

Nanologica AB (publ) Announces Nomination Committee for the Annual General Meeting 2024

Nanologica (STO:NICA) Is Making Moderate Use Of Debt

New minor risk - Financial position

Second quarter 2023 earnings released: kr0.41 loss per share (vs kr0.48 loss in 2Q 2022)

Is Nanologica AB (publ) (STO:NICA) Trading At A 40% Discount?

Chief Scientific Officer, Gary Pitcairn Will Leave Nanologica AB (publ)

First quarter 2023 earnings released: kr0.34 loss per share (vs kr0.56 loss in 1Q 2022)

Full year 2022 earnings: EPS and revenues miss analyst expectations

Insufficient new directors

No longer forecast to breakeven

Does Nanologica (STO:NICA) Have A Healthy Balance Sheet?

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Nanologica (STO:NICA) Is Making Moderate Use Of Debt

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to kr16.50

No longer forecast to breakeven

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Is Nanologica (NGM:NICA) A Risky Investment?

No longer forecast to breakeven

Third quarter 2021 earnings released: kr0.45 loss per share (vs kr0.32 loss in 3Q 2020)

Is Nanologica (NGM:NICA) Weighed On By Its Debt Load?

First quarter 2021 earnings released: kr0.28 loss per share (vs kr0.40 loss in 1Q 2020)

Full year 2020 earnings released: kr0.80 loss per share (vs kr1.18 loss in FY 2019)

Shareholders Are Thrilled That The Nanologica (NGM:NICA) Share Price Increased 115%

Nanologica Recruits PK Dutta as SVP Sales and Senior Advisor for Chromatography

New 90-day high: kr15.30

Nanologica AB (publ) Signs Collaboration Agreement with Zentiva for the Use of Nlab Drug Delivery Platforms

New 90-day high: kr13.80

Nanologica AB Engages Scientific Advisors Within Inhalation

Nanologica AB (Publ) Delivers Test Material from Large Scale Production

Nanologica AB (publ) to Report Q3, 2020 Results on Oct 30, 2020

New 90-day high: kr15.05

First half earnings released

New 90-day high - kr14.00

Nanologica AB (publ) to Report Q2, 2020 Results on Aug 21, 2020

Estabilidad y crecimiento de los pagos

Rentabilidad por dividendo vs. Mercado

Pago de beneficios a los accionistas

Pago en efectivo a los accionistas

Discover strong dividend paying companies